Compare SHOO & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHOO | RARE |
|---|---|---|
| Founded | 1990 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 1996 | 2013 |
| Metric | SHOO | RARE |
|---|---|---|
| Price | $43.64 | $27.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 20 |
| Target Price | $42.14 | ★ $59.10 |
| AVG Volume (30 Days) | 897.4K | ★ 2.2M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $2,534,109,000.00 | $673,000,000.00 |
| Revenue This Year | $12.39 | $13.12 |
| Revenue Next Year | $5.90 | $37.80 |
| P/E Ratio | $42.75 | ★ N/A |
| Revenue Growth | 11.00 | ★ 20.13 |
| 52 Week Low | $22.26 | $18.29 |
| 52 Week High | $47.11 | $39.89 |
| Indicator | SHOO | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 57.03 | 40.71 |
| Support Level | $43.03 | $21.54 |
| Resistance Level | $44.62 | $36.26 |
| Average True Range (ATR) | 1.43 | 1.35 |
| MACD | 0.15 | -0.90 |
| Stochastic Oscillator | 92.81 | 10.03 |
Steven Madden Ltd and its subsidiaries design, source, and market branded and private label footwear, accessories, and apparel. Its offerings include contemporary styles and core products, known for design creativity, trend-right offerings, high quality, and accessible price points. It operates through four segments: Wholesale Footwear, which generates maximum revenue and sells footwear globally; Wholesale Accessories/Apparel, which sells handbags and apparel through wholesale channels; Direct-to-Consumer, which sells footwear, handbags, apparel, and accessories through stores, outlets, e-commerce, and concessions; and Licensing, which licenses Steve Madden, Betsey Johnson, and Kurt Geiger trademarks, with the Company generating the majority of its revenue from the USA.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.